Biovica International Should Double On Novel Breast Cancer Test Launch In Q3

• Three months ago, I wrote an article for SA on Xbrane. I predicted a strong share price growth by the Phase 3 readout. Xbrane doubled.
• Biovica is a similar case. It should double in the next three months. For the same reasons as Xbrane did.
• Cancer diagnostics is a strongly evolving field. Biovica’s novel cancer test can detect breast cancer progress cheaper and much faster than current methods.
• Its unprecedented 30 clinical trials in the prominent US and European hospitals minimize the risk of FDA failure. Biovica expects FDA approval and US launch by the Q3 end.
• Share prices of pharma companies tend to move strongly before a major catalyst. Biovica should be a perfect example of this.

https://seekingalpha.com/article/4437698-biovica-international-should-double-on-novel-breast-cancer-test-launch-in-q3